Anzeige
Mehr »
Freitag, 15.08.2025 - Börsentäglich über 12.000 News
Neue Bohrergebnisse, Sichtgold und eine 7-fache Bewertungslücke, die zu groß ist, um sie zu ignorieren
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
72 Leser
Artikel bewerten:
(0)

Call to Action for a Consistent Care Pathway for Spastic Paresis Management

LONDON, January 17, 2017 /PRNewswire/ --

David Bowers, Klemens Fheodoroff, Patricia Khan, Julian P Harriss, Khashayar Dashtipour, Laxman Bahroo, Michael Lee, Denis Zakharov, Jovita Balcaitiene, Virgilio Evidente; European Neurological Review, 2016;11(2):87-95 DOI: https://doi.org/10.17925/ENR.2016.11.02.87

(Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

Published recently in European Neurological Review, the peer-reviewed journal from touchNEUROLOGY, David Bowers et al, highlight that, despite substantial impact on patients' independence and burden on caregivers, there is a lack of consensus on optimal management of spastic paresis and the patient journey remains unclear. A group of physicians, experienced in spasticity management, recently convened with the objective of analysing the patient journey from a care pathway perspective in different geographical regions and under different conditions from acute phase to long-term/chronic disease status. The experts reviewed results from recent patient and healthcare practitioner surveys on the subject and assessed how current patient pathways could be improved, using their own experiences to highlight the issues related to management deficiencies in their individual countries. The group divided the patient journey into steps, considering the evidence from the point of view of healthcare practitioners, patients, caregivers and funders/payors. This paper is a response to the lack of consensus on the optimal management of spastic paresis, and acts as a call to action to develop a consistent care pathway that could be applied across a broad range of illnesses, using an interdisciplinary approach.

The full peer-reviewed, open-access article is available here:

https://doi.org/10.17925/ENR.2016.11.02.87

Disclosure:David Bowers has participated in an advisory board for Ipsen and has been a trainer for Allergan and Medtronic. Klemens Fheodoroff has received unrestricted research grants from Ipsen and Merz, and honoraria for instructional courses from Ipsen, Allergan and Merz. Patricia Khan has participated in advisory boards for Ipsen, and has received honoraria for instructional courses from Ipsen and Allergan. Julian P Harriss has received research funding into current practice in spasticity management (the SPACE study, supported by Merz Pharma) and expenses for participation in expert panels (Ipsen). Khashayar Dashtipour has received compensation/honoraria for services as a consultant or an advisory committee member or speaker from Allergan, Inc., Ipsen Biopharmaceuticals, Inc., Lundbeck Inc., Merz Pharmaceuticals, Teva Pharmaceutical Industries Ltd., UCB Inc., Impax Pharmaceutical and US World Meds. Laxman Bahroo has received personal compensation from Teva Neuroscience, UCB pharma, Impax, Allergan, Ipsen, US World Meds, AbbVie, Lundbeck and Acadia for consulting, serving on a scientific advisory board or speaking activities, and research support from Ipsen and Teva Neuroscience. Michael Lee has participated in an advisory board for Ipsen. Denis Zakharov has received personal compensation from Ipsen and Merz for consulting, serving on a scientific advisory board or speaking activities. Jovita Balcaitiene is an employee of Ipsen Pharma. Virgilio Evidente has received research support from Ipsen and honoraria for consulting and/or speaking from Ipsen, Merz, Solstice, US WorldMeds, Lundbeck, UCB, Xenoport, Teva, Medtronic and Acadia. This article involves a review of a meeting and did not involve any studies with human or animal subjects performed by any of the authors.

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishes

European Neurological Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:

Carla Denaro - Managing Editor

T: +44 (0) 207 193 6093

managingeditor@touchmedicalmedia.com

Providing practical opinion to support best practice for busy healthcare professionals.

© 2017 PR Newswire
Tech-Aktien mit Crash-Tendenzen
Künstliche Intelligenz, Magnificent Seven, Tech-Euphorie – seit Monaten scheint an der Börse nur eine Richtung zu existieren: nach oben. Doch hinter den Rekordkursen lauert eine gefährliche Wahrheit. Die Bewertungen vieler Tech-Schwergewichte haben historische Extremniveaus erreicht. Shiller-KGV bei 39, Buffett-Indikator auf Allzeithoch – schon in der Dotcom-Ära war der Markt kaum teurer.

Hinzu kommen euphorische Anlegerstimmung, IPO-Hypes ohne Substanz, kreditfinanzierte Wertpapierkäufe in Rekordhöhe und charttechnische Warnsignale, die Erinnerungen an 2000 und 2021 wecken. Gleichzeitig drücken geopolitische Risiken, Trumps aggressive Zollpolitik und saisonale Börsenschwäche auf die Perspektiven.

Die Gefahr: Aus der schleichenden Korrektur könnte ein rasanter Crash werden – und der könnte vor allem überbewertete KI- und Chipwerte hart treffen.

In unserem kostenlosen Spezial-Report zeigen wir Ihnen, welche Tech-Aktien am stärksten gefährdet sind und wie Sie Ihr Depot vor dem Platzen der Blase schützen könnten.

Holen Sie sich den neuesten Report!

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.